Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Idea to Innovation

University of Toronto

$123,000.00

A condensation-driven platform for the synthesis of bioactive molecules

FY 2014-15

Summary
Synthesis of heterocycles is the centerpiece of both medicinal and process chemistry segments of drug discovery. Despite remarkable advances in organic chemistry, drug discovery and manufacturing continue to be extremely labour-intensive undertakings characterized by high attrition rates. An analysis of progress made to date shows that, while ever more complex molecules are being pursued, new ways to construct heterocyclic structures have received far less attention. Indeed, it appears that the majority of modern synthetic efforts to prepare bioactive heterocycles have concentrated on ways to cross-couple pre-functionalized modules. We became interested in developing hybrid strategies wherein installation of a C-B bond into a heterocycle operates concurrently with condensation-driven cyclization. This chemistry was found to proceed in a chemoselective manner, leading to atypical substitution patterns in products. As a result, rich forays into difficult-to-access heterocyclic chemistry space have become feasible. The University of Toronto elected to convert the provisional patent covering some aspects of this technology into a PCT application. We will capitalize on our advances and, in the span of 12 months, will focus our attention on scaling up four boron-containing building blocks (boroblocks, or BB's) and their derivatives. These activities will allow us to develop close ties with two collaborators: Alphora Research and AstraZeneca. In addition, Dr. Chris Thomas of Sigma-Aldrich has confirmed his company's intention to obtain a non-exclusive license for our technology from the University of Toronto. At the end of this project, we will have two commercial products: ""boroblocks"" (heterocycles equipped with C-B bonds at positions that are difficult to access) for API manufacturing and ""boro-kits"" (collections of proprietary boron-containing heterocycles for drug discovery). The value proposition is tremendous: by collaborating with Sigma-Aldrich, we will incur no marketing expenditures and will leverage their extensive network of customers to evaluate the utility of our compounds.
Program
Idea to Innovation
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
463146-2014
Name nom
Yudin, Andrei
Department département
Chemistry (St. George Campus)
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2014
Competition year année de concours
2014
Award amount
123000
Program id
I2IPJ
Program name en
Idea to Innovation
Program name fr
De l'idée à l'innovation
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
500
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Manufacturing processes and products
Area of application fr
Procédés et produits industriels
Research subject code
3704
Research subject group en
Organic chemistry
Research subject group fr
Chimie organique
Research subject en
Synthetic methodology
Research subject fr
Méthodologie en synthèse
Partie
1
Nb partie
1
Application title
A condensation-driven platform for the synthesis of bioactive molecules
Keyword
NSERC
Application summary
Synthesis of heterocycles is the centerpiece of both medicinal and process chemistry segments of drug discovery. Despite remarkable advances in organic chemistry, drug discovery and manufacturing continue to be extremely labour-intensive undertakings characterized by high attrition rates. An analysis of progress made to date shows that, while ever more complex molecules are being pursued, new ways to construct heterocyclic structures have received far less attention. Indeed, it appears that the majority of modern synthetic efforts to prepare bioactive heterocycles have concentrated on ways to cross-couple pre-functionalized modules. We became interested in developing hybrid strategies wherein installation of a C-B bond into a heterocycle operates concurrently with condensation-driven cyclization. This chemistry was found to proceed in a chemoselective manner, leading to atypical substitution patterns in products. As a result, rich forays into difficult-to-access heterocyclic chemistry space have become feasible. The University of Toronto elected to convert the provisional patent covering some aspects of this technology into a PCT application. We will capitalize on our advances and, in the span of 12 months, will focus our attention on scaling up four boron-containing building blocks (boroblocks, or BB's) and their derivatives. These activities will allow us to develop close ties with two collaborators: Alphora Research and AstraZeneca. In addition, Dr. Chris Thomas of Sigma-Aldrich has confirmed his company's intention to obtain a non-exclusive license for our technology from the University of Toronto. At the end of this project, we will have two commercial products: ""boroblocks"" (heterocycles equipped with C-B bonds at positions that are difficult to access) for API manufacturing and ""boro-kits"" (collections of proprietary boron-containing heterocycles for drug discovery). The value proposition is tremendous: by collaborating with Sigma-Aldrich, we will incur no marketing expenditures and will leverage their extensive network of customers to evaluate the utility of our compounds.
University of Toronto - $123,000 Grant (2014-15) | Canada Spends